top of page
AAO 2025: POSTERIOR RETINA SHOWCASE
Moderators: Rishi P. Singh, MD, Incoming Chair, Department of Ophthalmology, Mass Eye and Ear, Mass General Brigham and Lejla Vajzovic, MD, Program Committee
Panel: Allen C. Ho, MD, Retina Program Director and Charles C. Wykoff, MD, PhD, Program Committee
Room: W230
Start | Company | Presenter |
|---|---|---|
1:15 PM | Introduction | Rishi P. Singh, MD |
1:16 PM | Ikarovec | Thomas Ciulla, MD, MBA, President & CEO |
1:21 PM | Regenxbio | Steve Pakola, MD, Chief Medical Officer |
1:26 PM | Adverum Biotechnologies | Szilád Kiss, MD |
1:31 PM | 4DMT | Dhaval B. Desai, Chief Development Officer |
1:36 PM | Discussion | |
1:40 PM | Nanoscope Therapeutics | Sam Barone, MD, Chief Medical Officer |
1:45 PM | Kiora Pharmaceuticals, Inc. | Eric Daniels, MD, MBA, Chief Development Officer |
1:50 PM | Opus Genetics | Sally Tucker, PhD, SVP, Clinical Development |
1:55 PM | AAVantgarde Bio UK Limited | Natalia Misciattelli, PhD, CEO |
2:00 PM | Discussion | |
2:07 PM | EyeBio | Tony Adamis, MD, Co-Founder & Chief Scientific Officer |
2:12 PM | Surrozen | Dan Chao, VP, Clinical Development |
2:17 PM | Annexin Pharmaceuticals AB | Anna Frostegård, MD, PhD, Chief Scientific & Medical Officer |
2:22 PM | Discussion | |
2:26 PM | Aviceda Therapeutics | Jeffrey Nau, President & CEO |
2:31 PM | Astellas Pharma Global Development, Inc. | Marci English, MPH, SVP, Head of BioPharma & Ophthalmology Development |
2:36 PM | ONL Therapeutics | David Zacks, MD, PhD, Co-founder & Chief Scientific Officer |
2:41PM | Discussion | |
2:44 PM | Conclusion | Lejla Vajzovic, MD |
2:45 PM | End of Session |
Anchor 1
bottom of page